Cardiac risks associated with antibiotics: Azithromycin and levofloxacin

Expert Opinion on Drug Safety

Volumn 14, Issue 2, 2015, Pages 295-303

  Lu, Zhiqiang Kevin ^a,b,c,d   Yuan, Jing ^a   Li, Minghui ^a   Sutton, S Scott ^a,b   Rao, Gowtham A ^e   Jacob, Sony ^b,c   Bennett, Charles L ^a,b,c,d  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WJB Dorn VA Medical Center   (United States)

^c Southern Network on Adverse Reactions (SONAR) Project   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse drug reactions; Antibiotics; Azithromycin; Cardiac death; Cardiovascular risks; Drug safety; Infections; Levofloxacin; Review

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; LEVOFLOXACIN; ANTIINFECTIVE AGENT;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); HEART DEATH; HEART ELECTROPHYSIOLOGY; HUMAN; QT PROLONGATION; REVIEW; RISK ASSESSMENT; CHEMICALLY INDUCED; DEATH; LONG QT SYNDROME;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DEATH; HUMANS; LEVOFLOXACIN; LONG QT SYNDROME;

EID: 84921361868     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.989210     Document Type: Review

References (69)

1. Hicks LA, Taylor TH Jr, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med 2013;368(15):1461-2
2. IMS Institute for Healthcare Informatics. The use of medicines in the United States review of 2011. 2011
3. Food and Drug Administration. Levaquin® Utilization Trends, January 2004 to March 2011. 2011
4. Gilbert DN. Sanford guide to antimicrobial therapy. 43 edition. Antimicrobial Therapy; Sperryville, VA: 2013
5. Food and Drug Administration. Zmax® (azithromycin) BPCA Drug Use Review. 2010
6. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20):1881-90
7. Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014;12(2):121-7.
8. Federal Drug Comission. FDA/ PhRMA task force to assess QT risk by preclinical markers. The Pink Sheet; Chevy Chase, MD: 1999
9. Food and Drug Administration. FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. 2013
10. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368(18):1704-12.
11. Bazett HC. An analysis of the timerelations of electrocardiograms. Ann Noninvasive Electrocardiol 1997;2(2):177-94
12. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47(2):362-7
13. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348(19):1866-74
14. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22
15. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354(9190):1625-33
16. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010;55(9):934-47
17. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Jama 1993;270(21):2590-7
18. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf 2012;3(5):241-53
19. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006;43(12):1603-11
20. Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie 2010;65(9):631-40
21. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99(12):1540-7
22. Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003;361(9360):809-13
23. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003;290(11):1459-66
24. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352(16):1637-45
25. Granowitz EV, Tabor KJ, Kirchhoffer JB. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol 2000;23(9):1433-5
26. Arellano-Rodrigo E, Garcia A, Mont L, Roque M. [Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome]. Med Clin (Barc) 2001;117(3):118-19
27. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006;77(1):30-2
28. Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol 2005;28(11):1221-2
29. Samarendra P, Kumari S, Evans SJ, et al. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol 2001;24(10):1572-4
30. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003;116(1185):U666
31. Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 2007;30(12):1579-82
32. Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a cause of QTinterval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007;18(3):243-6
33. Del Rosario ME, Weachter R, Flaker GC. Drug-induced QT prolongation and sudden death. Mo Med 2010;107(1):53-8
34. Santos N, Oliveira M, Galrinho A, et al. QT interval prolongation and extreme bradycardia after a single dose of azithromycin. Rev Port Cardiol 2010;29(1):139-42
35. Winton JC, Twilla JD. Sudden cardiac arrest in a patient on chronic methadone after the addition of azithromycin. Am J Med Sci 2013;345(2):160-2
36. Strle F, Maraspin V. Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr 2002;114(10-11):396-9
37. Food and Drug Administration. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2012
38. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014;311(21):2199-208.
39. Paltoo B, O'Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 2001;24(5):895-7
40. Patel PD, Afshar H, Birnbaum Y. Levofloxacin-induced torsades de pointes. Tex Heart Inst J 2010;37(2):216-17
41. Gandhi PJ, Menezes PA, Vu HT, et al. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 2003;60(23):2479-83
42. Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005;39(3):543-6
43. Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11(1):52-6
44. Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73(4):292-303
45. Makaryus AN, Byrns K, Makaryus MN, et al. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event? South Med J 2006;99(1):52-6
46. Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128(5):3398-406
47. Juurlink DN. The cardiovascular safety of azithromycin. CMAJ 2014;186(15):1127-8
48. Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94(6):1471-4
49. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998;280(20):1774-6
50. Pham TV, Sosunov EA, Anyukhovsky EP, et al. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation 2002;106(16):2132-6
51. Wu Y, Anderson ME. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res 2002;53(3):763-9
52. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996;94(10):2535-41
53. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8(7):690-5
54. Pham TV, Sosunov EA, Gainullin RZ, et al. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 2001;103(17):2207-12
55. Albert RK, Schuller JL. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014;189(10):1173-80
56. Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011;183(3):303-7
57. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35(2):197-200
58. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303(1):218-25
59. Hagiwara T, Satoh S, Kasai Y, Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol 2001;87(3):231-4
60. Poluzzi E, Raschi E, Motola D, et al. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010;33(4):303-14
61. Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013;368(18):1665-8
62. Food and Drug Administration. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. 2013
63. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89(11):1363-72
64. Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of druginduced QT prolongation and torsade de pointes. Am Heart J 2007;153(6):891-9
65. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 2009;66(9):825-33
66. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-98
67. Berg HF, Maraha B, Scheffer GJ, et al. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis 2005;40(3):358-65
68. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Available from: http://www.pha.nu.ac.th/apirukw/dis/ uploads/8BA9E-Citing-Micromedex.pdf
69. Wong E, Nguyen TV. A case-based approach to evaluating azithromycin use and cardiovascular risks. Consult Pharm 2014;29(1):47-52